An open-label, randomized, controlled trial to assess the efficacy and safety of teprenone in chronic hepatitis C patients concurrent with chronic gastritis treated with peginterferon alpha-2b plus ribavirin. - A randomized trial of teprenone for chronic hepatitis C patients treated with combination therapy.

Department of Gastroenterology and Hepatology, Okayama University Hospital0 个研究点目标入组 200 人开始时间: 2009年3月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Allergic to peginterferon alpha-2b or other interferon preparations. 2. Allergic to vaccine or biological preparations. 3. Allergic to ribavirin or other nucleoside preparations. 4. Pregnant or under breast feeding. 5. Uncontrolled cardiovascular diseases. 6. Abnormal hemoglobinemia. 7. Chronic renal failure or creatinine clearance value less than 50 mL/min. 8. Severe depression or psychiatric disorders including a history of a suicide attempt. 9. Sever or decompensated liver disease or obstruction of biliary tract. 10. Vascular diseases of central nervous system. 11. Concomitant herbal medication such as Sho-saiko-to. 12. Autoimmune liver diseases. 13. Chronic liver diseases other than hepatitis C virus such as hepatitis B virus and excessive alcohol intake. 14. Other conditions considered inappropriate by attending physician.

发起方

Department of Gastroenterology and Hepatology, Okayama University Hospital